A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults
Completed
Glaxo Wellcome
Phase 4
1999-10-01
The purpose of this study is to see if a certain combination of anti-HIV drugs is safe and
effective in HIV-infected patients. The drug combination includes a tablet containing
lamivudine and zidovudine (called Combivir) plus abacavir plus efavirenz.
Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir)
Unknown status
Glaxo Wellcome
Phase 3
1969-12-31
The purpose of this study is to look at the safety and effectiveness of a pill called
Trizivir that is a combination of three anti-HIV drugs (zidovudine, lamivudine, and
abacavir). Zidovudine and lamivudine are often given combined in one pill (Combivir). In this
study, Trizivir will be compared to Combivir plus abacavir.
Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment
Unknown status
Glaxo Wellcome
Phase 4
1969-12-31
The purpose of this study is to see how effective and safe it is to give 1 of the 3 following
treatments to patients who may not have received anti-HIV treatment: 1) lamivudine
(3TC)/abacavir (ABC)/stavudine (d4T); 2) 3TC/ABC/efavirenz (EFV); or 3) 3TC/ABC/amprenavir
(APV)/ritonavir (RTV).
Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure
Completed
ViiV Healthcare
Phase 4
2002-03-01
This study is a 48-week study to evaluate the efficacy and safety of an investigational
regimen combining FDA approved HIV drugs in antiretroviral-experienced subjects failing on
their first highly active antiretroviral therapy regimen.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
